New Court Proceedings (May 2022)

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.

Explore Firm Details

Taro Pharmaceuticals v Biogen and Acorda Therapeutics.

Canada Litigation, Mediation & Arbitration

Authors

Section 8 Proceedings:

FAMPYRA (fampridine): Taro Pharmaceuticals v Biogen and Acorda Therapeutics

PM(NOC) Proceedings:

TRINTELLIX (vortioxetine): Lundbeck v Sandoz Canada
ODEFSEY (emtricitabine / rilpivirine / tenofovir alafenamide): Janssen Pharmaceutical v Apotex
DESCOVY (tenofovir alafenamide hemifurate): Gilead Sciences v Apotex
ODEFSEY (emtricitabine / rilpivirine / tenofovir alafenamide): Gilead Sciences v Apotex

For complete details about these proceedings, click here.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Authors

Nancy Pei

Your Author LinkedIn Connections

See More Popular Content From

New Court Proceedings (May 2022)

Contributor

Litigation, Mediation & Arbitration

Contributor

Canada